Posts tagged iPSC
Roth ups Evotec price target to €16

Roth Capital Partners raised its price target for “buy-rated Evotec AG (FSE:EVT) to €16 from €5.50, reflecting a review of the company’s partnered pipeline assets. The stock was recently quoted at €11.66.

Read More
Roth starts Fate Therapeutics at buy

Roth Capital Partners has launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and a target price of $8. The stock closed at $3.18 on Wednesday.

Analyst Mark Breidenbach writes that the company's lead asset, ProTmune, could address a serious unmet medical need in patients requiring hematopoietic transplants (HSCTs), and “we expect to see early clinical data by the end of 2016.”

Read More